Pacifor® Solution for Injection

Solution for injection.

Sedative – pre-anesthetic.

Each 1 mL of solution for injection contains:
Acepromazine Maleate ………………………. 10 mg
(Equivalent to 7.4 mg of Acepromazine base)
Excipients c.s.p……………………………………. 1 mL

Pacifor® Solution for Injection, it is indicated as a sedative and pre-anesthetic agent.

0.14 – 0.27 mL per 10 kg of body weight in a single dose, equivalent to 0.1 – 0.2 mg of acepromazine base per kilogram of body weight, in a single dose. Do not exceed doses of 3 mg total.

Intramuscular, intravenous, or subcutaneous.

After parenteral administration, animals should be kept in a quiet place until the onset of sedative effects, which occur at about 15 minutes. The effects can last for up to 3 hours. Intravenous administration should be slow. Administer aseptically.

Dogs.

• Do not administer intra-arterially.
• Do not administer in animals with hypovolemia or shock.
• Do not administer in animals with coagulopathies or thrombocytopenia.
• Do not administer in animals with tetanus or strychnine poisoning.
• Do not administer within one month of deworming with organophosphate agents

• Acepromazine generates vasodilation-mediated hypotension, which may last for a few hours. It is usually mild in healthy animals, however, it can be accentuated in anesthetized, debilitated or hypovolemic patients.
• Unusual cardiovascular collapse of variable severity (secondary to bradycardia and hypotension) has been described, especially in brachycephalic breeds.
• Acepromazine causes significant intraoperative hypothermia that lasts for a few hours.
• Acepromazine causes nictitating membrane prolapse, which lasts for a few hours.
• Acepromazine may decrease hematocrit transiently, restoring after several hours, which may be important in anemic animals.
• Acepromazine decreases platelet aggregation transiently without affecting clotting times.
• Occasionally, acepromazine may generate contradictory clinical signs of aggressiveness and generalized stimulation of the central nervous system. These reactions are rare and transient in nature and usually do not last longer than 48 hours.
• Intramuscular injections of Acepromazine may cause transient pain at the injection site.

• Intravenous administration should be done slowly.
• Following administration of acepromazine, lower doses of general anesthetics are required.
• Use with caution in regional anesthetic procedures with local anesthetics.
• Use with caution and at the lowest recommended dose in animals with hepatic dysfunction, heart disease, and general weakness.
• Use with caution in very young or debilitated animals. Use with caution in geriatric patients.
• Acepromazine does not have analgesic effects, steps should be taken to control pain.
• Use with caution on brachycephalic dogs (Boxers, Pekingese, etc.), on dogs with MDR1 mutations (Collies, Australian Shepherds, among others) and on giant breeds, Greyhounds and Terriers.
• Use with caution as a containment agent in aggressive dogs.
• It can be used in conjunction with Atropine to block its bradycardic effects.
• It is recommended to use eye lubricants or artificial tears as corneal protectors.
• A higher dose does not accelerate the onset of sedation, it only lengthens the sedative effect.
• Once it has been administered, it is important to leave the animal in a quiet place for about 15 minutes or until the sedative effects are achieved.
• After administration, patients should not be exposed to fluctuations in
  Extreme temperatures for at least 8 hours.
• Administration in conjunction with other respiratory or central nervous system depressants may exacerbate respiratory depression.
• Keep out of reach of children and pets.

• Acepromazine may exacerbate the action of Central Nervous System depressant agents if used together.
• Concomitant administration with epinephrine may lead to beta activity causing vasodilation and increased heart rate.
• Opioids may enhance the hypotensive effects of acepromazine.
• Acepromazine should not be administered within one month of deworming with organophosphate agents as its effects may be potentiated.
• Phenytoin metabolism may decrease if given simultaneously with phenothiazines. The activity of Procaine can be enhanced by phenothiazines.
• Co-administration of Acepromazine and Propanolol may lead to serum elevation of both drugs.
• Co-administration of quinidine with phenothiazines may cause additive cardiac depression.
• Vasoconstrictors, such as phenylephrine, antagonize the hypotensive effects of phenothiazines.

• In the case of ocular exposure, the eyes should be irrigated with plenty of water. If irritation exists and persists, the patient should be evaluated by a physician.
• In the case of dermal exposure, contaminated clothing should be removed or the exposed area should be washed thoroughly with water. If irritation is present and persists, the patient should be evaluated by a physician.
• In case of accidental ingestion, the mouth should be washed. If large amounts have been swallowed, immediate medical attention should be sought.
• In the case of accidental injection, immediate medical attention should be sought.

Discard the unused product in its original packaging. Dispose of empty containers of this product together with household waste. Contact the manufacturing company or companies specialized in waste disposal, to receive recommendations on the disposal of expired or unused products.

Not applicable.

Store at a temperature between 15° and 30°C, away from light.
Once opened, the container should be used within 3 months and should be stored at a temperature between 15 and 30ºC, away from light

Chile: Sale by prescription to the Veterinary Doctor.
Peru: Under prescription restricted.

VETERINARY USE
KEEP OUT OF REACH OF CHILDREN AND PETS.

Chile: Reg. SAG N° 2390
Bolivia: Reg. SENASAG PUV-F-N° 005506/13
Peru: Reg. SENASA F.62.01.I.0028
Costa Rica: Reg. No. MV-7152

Ampoule bottle with 10 mL and 50 mL

Laboratorio Drag Pharma Chile Invetec S.A.
Lautaro N° 300. Quilicura. Santiago. Chile.